Diseases of the intrahepatic bile duct: Diagnosis and treatments;Maladies des voies biliaires intrahépatiques: Diagnostic et principes du traitement

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 I, 2003, Pages 307-318

  Chazouillères, Olivier ^a   Wendum, Dominique ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID;

AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CHOLANGIOGRAPHY; CYSTIC FIBROSIS; ENDOSCOPY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTRAHEPATIC BILE DUCT; LIVER DISEASE; LIVER TRANSPLANTATION; OUTPATIENT DEPARTMENT; PARENTERAL NUTRITION; PATHOLOGY; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PUNCH BIOPSY; RADIOGRAPHY; REVIEW; SCLEROSING CHOLANGITIS;

ADULT; ALGORITHMS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BILE DUCT DISEASES; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CAUSALITY; CHILD; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; URSODEOXYCHOLIC ACID;

EID: 0344837740     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998;73:285-91.
2. Balasubramaniam K, Wiesner RH, Larusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988;95:1395-8.
3. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001;120:239-49.
4. Johanet C, Dubel L, Chazouillères O. Autoanticorps en hépatologie. Path Biol 1999;47:997-1005.
5. Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996;23:1020-4.
6. Pawlotsky JM, Andre C, Metreau JM, Beaugrand M, Zafrani ES, Dhumeaux D. Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis. Hepatology 1992;16:127-31.
7. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
8. Sapey T, Turlin B, Canva-Delcambre V, Mendler MH, Deugnier Y, Brissot P, et al. Interêt de la ponction-biopsie-hépatique et de la cholangiographie rétrograde endoscopique chez les malades ayant une cholestase chronique anictérique inexpliquée. Etude retrospective chez 79 malades. Gastroenterol Clin Biol 1999;23:178-85.
9. Zafrani ES, Degott C. Maladies non tumorales des voies biliaires intrahépatiques de l'adulte. Ann Pathol 1995;15:348-56.
10. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-12.
11. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999;29:1007-12.
12. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993;17:1272-80.
13. Larrey D, Michel H. Pathologie biliaire dûe aux médicaments. Gastroenterol Clin Biol 1993;17:H59-65.
14. Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985;88:108-14.
15. Portmann B, Nakanuma Y. Diseases of the bile ducts. In: MacSween RNM, Burt AD, Portmann B, Ishak KG, Scheuer PJ, P. AP, eds. Pathology of the liver. London: Churchill Livingstone, 2002:435-506.
16. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A, et al. Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Mod Pathol 1994;7:937-45.
17. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65.
18. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870-7.
19. Olsson R, Hagerstrand I, Broome U, Danielsson A, Jarnerot G, Loof L, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995;48:933-5.
20. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000;32(1):129-40.
21. Zafrani ES, Tran Van Nhieu J. La biopsie hépatique dans l'exploration d'une cholestase. In: Groupe METAVIR, ed. La biopsie hépatique en pathologie non tumorale du foie. Paris: Elsevier, 2000:75-96.
22. Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993;17:70-7.
23. Baron TH, Koehler RE, Rodgers WH, Fallon MB, Ferguson SM. Mast cell cholangiopathy: another cause of sclerosing cholangitis. Gastroenterology 1995;109:1677-81.
24. Kaplan KJ, Goodman ZD, Ishak KG. Liver involvement in Langerhans'cell histiocytosis: a study of nine cases. Mod Pathol 1999;12:370-8.
25. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988;7:193-9.
26. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998;28:323-31.
27. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000;31:792-9.
28. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777-90.
29. Desmet V, Roskams T, Van Eyken P. Ductular reaction in the liver. Pathol Res Pract 1995;191:513-24.
30. Scheuer PJ, Lefkowitch JH. Assessment and differential diagnosis of pathological features. In: Saunders WB, ed. Liver biopsy interpretation. London: Harcourt Publishers Limited, 2000:51-65.
31. James O. Definition and epidemiology of primary biliary cirrhosis. In: J. Neuberger, ed. Primary biliary cirrhosis. Eastbourne: West End Studios, 2000:53-9.
32. Christensen E, Crowe J, Doniach D, Popper H, Ranek L, Rodes J, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980;78:236-46.
33. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-40.
34. Grambsch PM, Dickson ER, Kaplan M, Lesage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989;10:846-50.
35. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999;29:39-43.
36. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35:260-5.
37. Invernizzi P, Grosignani A, Battezzati PM, Covini G, De Valle G, Larghi A et al. Comparison of the clinical features and clinical course of antimitochondrial antibody positive and negative primary biliary cirrhosis. Hepatology 1997;25:1090-5.
38. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
39. Chazouillères O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score ? J Hepatol 2000;33:661-3.
40. Lhose AW, Meyer Zum Büschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
41. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399-1402.
42. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;6:924-33
43. Li-yeng C, Goldberg HJ. Sclerosing cholangitis: broad spectrum of radiographic features. Gastrointest Radiol 1984;9:39-47.
44. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995;21:661-7.
45. Van den Hazel SJ, Wolfhagen EH, van Buuren HR, van de Meeberg PC, van Leeuwen DJ. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000;32:779-82.
46. Angulo P, Pearce DH, Johnson D, Henry JJ, LaRusso NF, Petersen BT, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000;33:520-7.
47. Fulcher AS, Turner MA, Franklin KJ, Shiffman ML, SterlinG RK, Luketic VAC, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography - a case-control study. Radiology 2000;215:71-80.
48. Haider MA, Bret PM. The role of magnetic resonance cholangiography in primary-sclerosing cholangitis. J Hepatol 2000;33:659-60.
49. Terada T, Nakanuma Y. Intrahepatic cholangiographic appearance simulating primary sclerosing cholangitis in several hepatobiliary diseases: a postmortem cholangiographic and histopathological study in 154 livers at autopsy. Hepatology 1995;22:75-81.
50. Broome U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994;35:84-9.
51. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51:562-6.
52. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming T, Ludwig J, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-901.
53. Brentnall TA, Haggit RC, Rabinovitch PS, Kimmery MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8.
54. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
55. Leidenius M, Hökerstedt K, Broomé U, Ericzon BG, Friman S, Olausson M, Schrumpf E. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. J Hepatol 2001;34:792-8.
56. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-9.
57. Kubicka S, Kühnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001;48:403-8.
58. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28: 700-6.
59. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991;11:11-7.
60. Broomé U, Glaumann H, Lindstöm E, Lööf L, Almer S, Prytz H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J. Hepatol 2002;36:586-9.
61. Björnsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731-5.
62. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002;35:1494-1500.
63. Gohlke F, Lohse AW, Dienes HP, Löhr H, Märker-Hermann E, Gerken G, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. Hepatology 1996;24:699-705.
64. Wilschanksi M, Chait P, Wade JA, Davis L, Corey M, St Louis P, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-21.
65. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
66. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36:1393-9.
67. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51.
68. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
69. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
70. Lindor KD, for the Mayo Primary Sclerosing Cholangitis- Ursodeoxycholic acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
71. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
72. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9.
73. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-8.
74. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94:488-93.
75. Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-25.
76. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;31:318-23.
77. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walkern S, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. J Hepatol 1997;26:560-6.
78. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, Zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943-6.
79. Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, Klintmalm GB, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989;320:1709-13.
80. Abu-Elmagd KM, Malinchoc M, Dickson ER, Fung JJ, Murtaugh PA, Langworthy AL, et al. Efficacy of hepatic transplantation in patients with pimary sclerosing cholangitis. Surg Gynecol Obstet 1993;177:335-44.
81. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997;3:628-37.